Join Model N to learn market trends and strategies for optimal global pricing
REDWOOD CITY, Calif. – February 23, 2016 – Model N, Inc. (NYSE: MODN), the leading provider of cloud-based Revenue Management solutions to life science, technology and manufacturing companies, announces its bronze sponsorship for the World Pharma and Market Access Congress 2016. The Congress is being held 23-25 February 2016 at the Victoria Park Plaza in London, UK.
Model N brings deep thought leadership and industry expertise with a top-tier pharmaceutical roster, including Amgen, AbbVie, Gilead, Janssen Pharmaceuticals, Sanofi and others. During the forum, Model N will share industry trends and best practices that are shaping selling and pricing in pharmaceuticals. Model N will also be on hand to illustrate its Global Pricing Management solution that drives better price decisions and price execution.
Securing broad patient access, whilst protecting the value of pharmaceutical assets is a tough balancing act for manufacturers today,” says James Robinson, Director of Model N. “Multiple target indications, price referencing, outcomes based agreements and stringent HTA criteria are all driving increasingly innovative strategies. Global pricing and market access teams are demanding more sophisticated scenario analytics and tighter controls over pricing policy from gross to net.”
Due to the dynamic evolution of the pricing space, continuous innovation in this field is becoming a strategic focus for pricing teams in the pharmaceutical industry. Model N is a thought leader in pricing and profit optimization and leads the way by innovating together with its customers. During the conference, Model N will present alongside customer Sanofi to review the challenges in monetizing innovations equitably, market trends impacting pricing strategy and execution and lessons to manage optimal outcomes.
“Developing our internal capabilities to plan for, assess and react to a more dynamic pricing landscape is fundamental to generating sustainable growth across a diversified portfolio and improving patient access to medicines and quality healthcare,” says Barrie Gilligan, Global Pricing Policy Director, Sanofi
At the forum, Model N will review the findings from the recent Global Pricing Benchmarking survey conducted by Model N and HighPoint Solutions. It offers a unique opportunity to discover the 5 top perceived success factors for pricing excellence across the globe.
Please join Model N and Sanofi on February 24 at 2:50 PM for a presentation on “Optimising Global Pricing Strategies for Patient Access and Margin Protection” or stop by Stand #14 for more information.
About Model N
Model N is the leader in Revenue Management Cloud solutions for life science, technology and manufacturing companies. Driving mission critical business processes such as configure, price and quote (CPQ), contract management, rebates and regulatory compliance, Model N Cloud solutions transform the revenue lifecycle from a series of disjointed operations into a strategic end-to-end process. With deep industry expertise, Model N supports the unique business needs of the world’s leading brands in life science, technology and manufacturing across more than 100 countries. Model N is a trusted partner to some of the world’s largest brands, including Johnson & Johnson, AstraZeneca, Boston Scientific, Novartis, Ortho Clinical Diagnostics, Atmel, Fairchild and Marvell. Model N trades on the New York Stock Exchange under the symbol MODN. Model N® is the registered trademark of Model N, Inc. Any other company names mentioned are the property of their respective owners and are mentioned for identification purposes only.
+1 (650) 610-4667